Additionally, due to the presence of mesenchymal tumors and defects in vasculogenesis present in patients with ECCL, it has also been hypothesized that a mutation in a gene similar to the transcription factor HMG2A may be involved [4]. The gene discussed is HMGB3; the disease is mesenchymal cell neoplasm.